RCUSArcus Biosciences, Inc.Finished
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Non Small Cell Lung Cancer · Nonsquamous Non Small Cell Lung Cancer · Squamous Non Small Cell Lung Cancer · Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 169 (final count)
- Started
- Feb 8, 2021
- Main results expected
- Sep 17, 2026
- Fully finished
- Sep 17, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: From randomization until death from any cause (up to 7 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04736173 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC